This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

A new Houston Methodist Research Institute study finds that older adults with metabolic dysfunction-associated steatotic liver disease (MASLD) who received GLP-1-based treatment experienced significantly lower risks of liver disease–related complications, hospitalization and death compared with similar patients who did not receive the treatment.

Researchers found that patients receiving GLP-1 therapy had a 28% lower risk of hepatic decompensation, a serious complication of advanced liver disease, and a 45% lower risk of death from any cause. They also experienced fewer hospitalizations during follow-up.

Published in Age and Ageing, the study was led by Eleftherios Mylonakis, M.D., Ph.D., professor of medicine at Houston Methodist Research Institute and chair of the Department of Medicine at Houston Methodist.

"Our findings suggest that the potential benefits of GLP-1-based treatments may extend well beyond weight loss and glycemic control," Mylonakis said. "Importantly, these findings were observed in older adults, a population that has been underrepresented in many previous studies evaluating these medications."

S. health care organizations, and compared 43,930 adults aged 65 and older who started GLP-1 therapy with 43,930 matched patients who did not receive the medications. 8 years, and women represented 62% of the study population. The study applied statistical methods to ensure the groups were comparable in age, health conditions, medications and laboratory values before evaluating their outcomes.

Source link